3Indexed trials
drug · Product Intelligence
Temozolomide
Pipeline Intelligence
Temozolomide: 3 indexed trials, 3 sponsors; 0 linked Orange Book patents and 5 FDA-linked events where matched.
3Sponsors
0Orange Book patent links
5FDA-linked events
Development evidence
NCT02193347Katy Peters, MD, PhD · neuro_oncologyPHASE1
NCT03425292Saint John's Cancer Institute · neuro_oncologyPHASE1
NCT05664464University of Zurich · epilepsyPHASE1, PHASE2
FDA / patent evidence
Orange Book match found; no listed patent relation was retained for this product match.
Regulatory context
FDA_APPROVALTEMOZOLOMIDE · 2017-04-26
FDA_APPROVALTEMOZOLOMIDE · 2017-04-18
FDA_APPROVALTEMOZOLOMIDE · 2016-07-13
FDA_APPROVALTEMOZOLOMIDE · 2014-02-12
FDA_APPROVALTEMODAR · 2009-02-27
FDA Orange Book coverage is U.S.-specific and is not a substitute for worldwide patent or regulatory review.